ONCAlert | 2018 ASCO Annual Meeting

Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab

Lyudmila A. Bazhenova, MD
Published Online: Sep 01,2017

Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the factors to take into consideration when treating a patient with non-driver non–small cell lung cancer with bevacizumab (Avastin).


Clinical Articles

Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.